XpresCheck™ Opens COVID-19 Testing Facility at Seattle-Tacoma International Airport
XpresCheck is a pop-up facility that is located pre-security inside the terminal, in the Baggage Claim area near Carousel 9. Eight separate testing rooms provide the capacity to administer over 500 tests per day. COVID-19 testing options include the Rapid Molecular COVID-19 Test and the Polymerase Chain Reaction (PCR) Test.
“By expanding our preventative and safety measures with the arrival of XpresCheck, this adds to our layered and comprehensive response to protect your health and well-being. The pandemic paused travel for the last year, and rightly so. Now, travelers are more comfortable booking trips with the right planning and precautions to stay healthy. Having easy access to a testing site at the airport is part of how we’re evolving with travelers during the pandemic,” added SEA Managing Director
The testing is by appointment for ticketed passengers up to 72 hours prior to travel. Testing is available seven days a week from
If you test positive, Public Health and the
If you’re departing or connecting from SEA and seeking a COVID-19 test before travel, check the guidance by destination to understand if a COVID-19 test is needed.
COVID-19 testing at SEA is also available with Discovery Health MD through April. Read online for information on additional testing options.
Operated by the
Forward-Looking Statements This press release may contain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These include statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "estimates," "projects," "intends," "should," "seeks," "future," "continue," or the negative of such terms, or other comparable terminology. In particular, these statements include, without limitation, statements about our expectations relating to our new XpresCheck™ concept, being able to expand testing to other communicable diseases as well as administer vaccinations for the seasonal flu, our positioning to be part of the national rollout of various COVID-19 vaccinations as they become available, the degree to which our public testing model assists passengers meet testing requirements in select states and countries, our ability to identify and gain access to the latest and best COVID-19 testing methodologies and equipment, and our ability to further expand our initial sites and our overall ability to manage the regulatory challenges associated with this business line. Forward-looking statements relating to expectations about future results or events are based upon information available to
Source: XpresSpa Group, Inc.